1992
DOI: 10.1155/1993/567478
|View full text |Cite
|
Sign up to set email alerts
|

A Prospective Randomized Trial of Imipenem‐Cilastatin Versus Clindamycin/Tobramycin in the Treatmentof Intra‐Abdominal and Pelvic Infections

Abstract: THE CANADIAN C LINICAL TRIALS G ROUPLAOBJECTIVE: A Canadian multicentre clinical trial in the treatment of intra-abdominal and pelvic infections to compare the efficacy and safety of monotherapy using imipen em-cllastatin (imipenem) (500 mg intravenously every 6 h) versus combination therapy with clindamycin/ tobramycin (clindamycin 600 mg intravenously every 6 h and tobramycin l. 7 mg/kg intraven ously every 8 h). METHoDs: Two hundred and fifty patients were entered (88 definite and 162 possible infections) a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

1998
1998
2020
2020

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 8 publications
(1 citation statement)
references
References 26 publications
0
1
0
Order By: Relevance
“…No drug‐related instances of nausea or vomiting were reported in this study. Previous studies, mostly (but not exclusively) in neutropenic patients, have found nausea and vomiting to be a problem with imipenem/cilastatin [35–39]. In contrast, nausea and vomiting is not a significant problem with meropenem, even after bolus administration of the drug [7].…”
Section: Discussionmentioning
confidence: 99%
“…No drug‐related instances of nausea or vomiting were reported in this study. Previous studies, mostly (but not exclusively) in neutropenic patients, have found nausea and vomiting to be a problem with imipenem/cilastatin [35–39]. In contrast, nausea and vomiting is not a significant problem with meropenem, even after bolus administration of the drug [7].…”
Section: Discussionmentioning
confidence: 99%